Chris Tame

Chris has over 18 years experience in drug discovery, working across all preclinical phases, from Target ID to Candidate Selection. Chris started his career in 2007 as a medicinal chemist at  GSK and was part of the group that pioneered PROTACs through a collaboration with Craig Crews and Alessio Ciulli. In 2017 he moved to BenevolentAI and led techbio teams in target ID and early discovery chemistry, including the BAI-AZ collaboration in IPF. In 2024 he founded Ternary Therapeutics, a techbio company with a novel computational platform for the design of molecular glues. Ternary is based in London, UK.